middle.news

Why Are Botanix’s Sofdra Sales Surging 28% This Quarter?

8:34am on Tuesday 27th of January, 2026 AEDT Healthcare
Read Story

Why Are Botanix’s Sofdra Sales Surging 28% This Quarter?

8:34am on Tuesday 27th of January, 2026 AEDT
Key Points
  • Sofdra net revenue up 28% to $9.1 million in Q2 FY26
  • Total prescriptions shipped increased 24% quarter-on-quarter
  • Operating cash outflow rose due to 23 new sales hires and start-up costs
  • Strong market acceptance with 90% of healthcare professionals planning increased prescribing
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Botanix Pharmaceuticals (ASX:BOT)
OPEN ARTICLE